$AGMB

AgomAb Therapeutics NV

CIK:0002020932|SEC Filings

Consolidated statement of profit or loss - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Consolidated statement of profit or loss
Research and development expenses	€ (48,877)	€ (39,310)	€ (26,311)
General and administrative expenses	(12,791)	(10,133)	(6,097)
Total operating expenses	(61,668)	(49,443)	(32,408)
Other operating income	2,393	1,422	1,218
Operating loss	(59,275)	(48,021)	(31,190)
Changes in fair value of financial liabilities	(4,857)	848	18,964
Financial expenses	(133)	(357)	(86)
Financial income	1,718	1,267	303
Loss before taxes	(62,547)	(46,263)	(12,009)
Income tax (expense)/income		(4)	619
Loss for the year	€ (62,547)	€ (46,267)	€ (11,390)
Weighted average number of common shares outstanding, Basic	541,126	541,126	541,126
Weighted average number of common shares outstanding, Diluted	541,126	541,126	541,126
Basic loss per share (in €)	€ (143.22)	€ (107.09)	€ (35.63)
Diluted loss per share (in €)	€ (143.22)	€ (107.09)	€ (35.63)

Consolidated statement of cash flows - EUR (€)	12 Months Ended
Consolidated statement of cash flows - EUR (€)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net loss for the year	€ (62,547,000)	€ (46,267,000)	€ (11,390,000)
Adjustments for non-cash items:
Current income tax expense (income)		4,000	3,000
Deferred income tax expense (income)			(622,000)
Fair value (gain) loss on financial assets	(96,000)
Fair value (gain) loss on financial liabilities	4,857,000	(848,000)	(18,964,000)
Depreciation & amortization	219,000	311,000	99,000
Share-based payment expenses	5,355,000	1,071,000	2,159,000
Net foreign exchange losses (gains)	57,000	231,000
Interest expense	69,000	77,000	86,000
Interest income	(1,614,000)	(1,218,000)	(303,000)
Operating cash flows before movements in working capital	(53,700,000)	(46,640,000)	(28,932,000)
movements in working capital:
Decrease/(increase) in other current assets	(2,337,000)	(315,000)	1,343,000
Decrease/(increase) in other non-current assets	(363,000)	(342,000)	(331,000)
Increase / (decrease) in trade and other payables.	2,359,000	(230,000)	3,686,000
Increase/(decrease) in deferred income	747,000	(395,000)	(580,000)
Income taxes paid		(4,000)	(3,000)
Interest paid	(69,000)	(10,000)	(20,000)
Interest received	1,622,000	1,106,000	245,000
Net cash flow from /(used in) operating activities	(51,741,000)	(46,828,000)	(24,592,000)
Cash flows from investing activities
Purchases of property, plant and equipment	4,000	675,000
Purchase of financial investments	(30,000,000)		40,000,000
Payment of contingent consideration from previous acquisition	(3,000,000)
Net cash flow from /(used in) investing activities	(33,004,000)	(675,000)	40,000,000
Cash flows from financing activities
Repayment of lease liabilities	(338,000)	(163,000)	(100,000)
Proceeds from capital increase		97,055,000	79,871,000
Share issue costs		(129,000)	(453,000)
Other financial expense, net			6,000
Net cash flow from /(used in) financing activities	(338,000)	96,762,000	79,324,000
Net increase/(decrease) in cash and cash equivalents	(85,083,000)	49,260,000	94,732,000
Cash and cash equivalents at beginning of year	171,459,000	122,402,000	27,670,000
Effect of foreign exchange rate changes	45,000	(204,000)
Cash and cash equivalents at end of year	€ 86,418,000	€ 171,459,000	€ 122,402,000

Consolidated statement of financial position - EUR (€)	Dec. 31, 2025	Dec. 31, 2024
Non-current assets
Intangible assets	€ 20,110,000	€ 20,110,000
Goodwill	8,612,000	8,612,000
Property, plant and equipment	503,000	619,000
Right-of-use assets	1,083,000	1,373,000
Other financial assets	11,000	12,000
Other non-current assets	2,150,000	1,787,000
Total non-current assets	32,469,000	32,513,000
Current assets
Other current assets	4,723,000	2,386,000
Current financial investments	30,096,000
Cash and cash equivalents	86,418,000	171,459,000
Total current assets	121,237,000	173,845,000
Total assets	153,706,000	206,358,000
Equity
Share capital	223,072,000	223,072,000
Share premium reserve	76,634,000	76,634,000
Retained earnings	(181,714,000)	(119,181,000)
Share-based payment reserves	13,877,000	8,522,000
Other reserves	(967,000)	(966,000)
Equity attributable to the owners of the parent	130,902,000	188,081,000
Total equity	130,902,000	188,081,000
Non-current liabilities
Non-current lease liabilities	1,005,000	1,272,000
Non-current contingent consideration	3,210,000	7,879,000
Total non-current liabilities	4,215,000	9,151,000
Current liabilities
Current lease liabilities	249,000	273,000
Current contingent consideration	6,526,000
Trade and other payables	10,266,000	8,052,000
Deferred income and accrued charges	1,548,000	801,000
Total current liabilities	18,589,000	9,126,000
Total liabilities	22,804,000	18,277,000
Total equity and liabilities	€ 153,706,000	€ 206,358,000